IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Status:
Recruiting
Trial end date:
2025-10-21
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the
anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1
monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy
(platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung
cancer (ES-SCLC).